REVB - Revelation Biosciences, Inc.
Pre-Market:
Chart Events
Hammer
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 1.0200 |
| Open | 1.0200 |
| Bid | 0.0000 x 1000 |
| Ask | 1.0100 x 800 |
| Day's Range | 0.9893 - 1.0315 |
| 52 Week Range | 0.9510 - 67.9000 |
| Volume | |
| Avg. Volume | 734,042 |
| Market Cap | 6.17M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 0.02 |
| EPS (TTM) | 63.1500 |
| Earnings Date | Aug 14, 2023 - Aug 18, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.00 |
Fair Value
Related Research
Business WireRevelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress
SAN DIEGO, May 22, 2023--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its three months ended March 31, 2023 financial results and highlighted recent corporate progress.
Business WireRevelation Biosciences Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Recent Corporate Progress
SAN DIEGO, March 30, 2023--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its year end 2022 financial results and highlighted recent corporate progress.
Business WireRevelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board
SAN DIEGO, March 13, 2023--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment of disease, today announced it has appointed Julia Bohannon, Ph.D. and Antonio Hernandez, M.D. to its scientific advisory board. Dr. Hernandez and Dr. Bohannon are inventors of the phosphorylated hexaacyl disaccharide (PHAD) based technology licensed from Vanderbilt Univers
Business WireRevelation Biosciences Inc. to Participate in a Fireside Chat at the 35th Annual Roth Conference
SAN DIEGO, March 06, 2023--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced today that its Chief Executive Officer James Rolke will participate in a fireside chat at the 35th Annual Roth Conference scheduled for March 12-14, 2023 to be held at The Ritz Carlton, Laguna Niguel in Dana Point, California.
Business WireRevelation Biosciences Inc. Announces Closing of $15.6 Million Public Offering
SAN DIEGO, February 13, 2023--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today announced the closing on February 13, 2023 of its previously announced public offering of 2,888,600 shares of its common stock and 336,400 pre-funded warrants to purchase shares of common stock, together with warrants to purchase up to 6,
Business WireRevelation Biosciences Inc. Announces Pricing of $15.6 Million Public Offering
SAN DIEGO, February 09, 2023--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today announced the pricing of a public offering of 3,225,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 6,450,000 shares of its common stock at an offering price to the public of $4.83 pe
- Business Wire
Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300
SAN DIEGO, February 07, 2023--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation") announced today statistically significant results in a validated preclinical model of acute and chronic kidney disease. This mechanistic biomarker data further supports the potential clinical utility of REVTx-300 previously announced on November 18, 2022.
Business WireRevelation Biosciences Inc. Announces 1-for-35 Reverse Stock Split effective February 1, 2023 and Results of Special Meeting of Stockholders
SAN DIEGO, January 31, 2023--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation") announced today that, on February 1, 2023, the Company will implement a 1-for-35 reverse split of its common stock following approval at its Special Meeting of Stockholders held on January 30, 2023. The reverse stock split will be effective as of the morning of February 1, 2023, and the Company’s common stock will trade on a post-split basis at the beginning of trading on the same date under t
Business WireRevelation Biosciences Inc. Announces Mandatory Unit Separation to Occur on January 13, 2023
SAN DIEGO, January 10, 2023--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), announced today that, on January 13, 2023, the Company’s units, which trade with the ticker symbol "REVBU" will be mandatorily separated and the units will no longer trade on the Nasdaq Capital Market. Each unit is comprised of one share of the Company’s common stock and one warrant that entitles the holder to purchase one share of common stock at price of $11.50 per share. In the separation,
Business WireRevelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model
SAN DIEGO, Calif., November 18, 2022--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced that recently completed exploratory biomarker analysis has confirmed clinical development plans for REVTx-300 in the treatment of CKD and AKI. This new biomarker data is in addition to the previously-announced significant reduction in
Business WireRevelation Biosciences Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Recent Corporate Progress
SAN DIEGO, November 10, 2022--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its third quarter 2022 financial results and highlighted recent corporate progress.
Business WireRevelation Biosciences Inc. Announces Positive Results in Preclinical Model of Acute and Chronic Kidney Disease
SAN DIEGO, October 25, 2022--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced positive results in a preclinical model of acute kidney injury (AKI), chronic kidney disease (CKD). Treatment with REVTx-300 significantly reduced renal cortical fibrosis in a dose dependent manner in the medium and high dose groups (21.7% redu
Business WireRevelation Biosciences Inc. and Vanderbilt University Enter Exclusive Worldwide License Agreement
SAN DIEGO, October 06, 2022--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced an exclusive worldwide license agreement with Vanderbilt University, Nashville TN, USA (Vanderbilt) to develop and commercialize phosphorylated hexaacyl disaccharide (PHAD), for treating or preventing infections.
GlobeNewswireRevelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Recent Corporate Progress
SAN DIEGO, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today reported its second quarter 2022 financial results and highlighted recent corporate progress. Recent Corporate Progress Most recently in July, we completed a $5 million public offering.We continue to explore the possible ef
- GlobeNewswire
Revelation Biosciences Inc. Announces Closing of $5 Million Public Offering
SAN DIEGO, July 29, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment of disease, today announced the closing on July 28, 2022 of its previously announced public offering of 8,333,334 shares of its common stock, together with warrants to purchase up to 8,333,334 shares of its common stock at an offering price
- GlobeNewswire
Revelation Biosciences Inc. Announces Pricing of $5 Million Public Offering
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment of disease, today announced the pricing of a public offering of 8,333,334 shares of its common stock, together with warrants to purchase up to 8,333,334 shares of its common stock at an offering price to the public of $0.60 per share and ass
- GlobeNewswire
Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis
SAN DIEGO, July 22, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today announced topline data for its Phase 1b CLEAR clinical study to evaluate the effect of intranasal REVTx-99b on nasal challenge allergen in participants with allergic rhinitis to rye grass pollen. The primary endpoint to eva
- GlobeNewswire
Revelation Biosciences Inc. Completes Database Lock for its Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis
-Topline Data expected in the last week of July-SAN DIEGO, July 14, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today announced data base lock for its Phase 1b CLEAR clinical study to evaluate the effect of intranasal REVTx-99b on nasal challenge allergen in participants with allergic rhiniti
- GlobeNewswire
Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis
-Data anticipated in Q3 2022-SAN DIEGO, June 13, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today announced that it has completed enrollment and dosing of its Phase 1b CLEAR clinical study to evaluate safety and efficacy of intranasal REVTx-99b for the treatment of allergic rhinitis. Allergi